Sumatriptan: A pharmacoeconomic review of its use in migraine

PharmacoEconomics

Volumn 11, Issue 5, 1997, Pages 473-490

  Coukell, Allan J ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIHYDROERGOTAMINE MESILATE; ERGOTAMINE TARTRATE; METOCLOPRAMIDE; SUMATRIPTAN;

COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FLUSHING; HUMAN; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030946563     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711050-00009     Document Type: Review

References (57)

1. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994 Apr; 47: 622-51
2. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 19-28
3. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992 Aug; 12: 221-8
4. Kryst S, Scherl E. A population-based survey of the social and personal impact of headache. Headache 1994 Jun; 34: 344-50
5. Henry P, Michel P, Brochet B, et al. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992 Aug; 12: 229-37
6. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994; 34 Suppl. 2: 6-11
7. Lipton RB, Stewart WF, Celentano DD, et al. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992 Jun; 152: 1273-8
8. Hopkins A. The epidemiology of headache and migraine, and its meaning for neurological services. Schweiz Med Wochenschr 1996 Jan 27; 126: 128-35
9. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992 Jan 1; 267: 64-9
10. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993 May; 20: 131-7
11. Clarke CE, MacMillan L, Sondhi S. Economic and social impact of migraine. Q J Med 1996 Jan; 89: 77-84
12. Welch KMA. Drug therapy of migraine. N Engl J Med 1993 Nov 11; 329: 1476-83
13. Chustecka Z. New migraine agents approaching the market. Scrip 1996; 2166: 26
14. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Arch Neurol 1996; 53: 1132-7
15. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992 Jul; 2(1): 67-76
16. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993 Jan; 33: 29-35
17. Van Roijen L, Essink-Bot M-L, Koopmanschap MA. Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics 1995 Feb; 7 (2): 170-9
18. Bosanquet N, Zammit-Lucia J. Migraine: prevention or cure? Br J Med Econ 1992; 2: 81-91
19. Blau JN, Drummond MF, editors. Migraine. London: Office of Health Economics, 1991
20. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103-15
21. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992 Jul; 2 (1): 1-4
22. Davey PJ, Leeder SR. The cost of migraine: more than just a headache? Pharmacoeconomics 1992 Jul; 2 (1): 5-7
23. de Lissovoy G. Lazarus SS. The economic cost of migraine. Present state of knowledge. Neurology 1994 Jun; 44 Suppl. 4: S56-62
24. Dahlöf CGH, Dimenäs E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995 Feb; 15: 31-6
25. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994 Jun; 34: 337-43
26. Solomon GD. Quality-of-life assessment in patients with headache. Pharmacoeconomics 1994 Jul; 6(1): 34-41
27. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the Medical Outcomes Study Instrument. Headache 1993 Jul-Aug; 33: 351-8
28. Dechanf KL, Clissold SP. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of migraine and cluster headache. Drugs 1992 May; 43: 776-98
29. Harrison DL, Slack MK. Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache. J Pharm Technol 1996 May-Jun; 12: 109-14
30. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriplan in the treatment of acute migraine. Arch Neurol 1996 Feb; 53: 180-4
31. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995 Oct 7; 346: 923-6
32. Multinational oral sumatriptan and cafergot comparative study group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991 Sep-Oct; 31: 314-22
33. Oral sumatriptan and aspirin plus metoclopramide comparative study group. A study to compare oral sumatriplan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992 May-Jun; 32: 177-84
34. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21
35. Dahlöf CGH. How does sumatriptan perform in clinical praclice? Cephalalgia 1995 Oct; 15 Suppl. 15: 21-8
36. Dahlof C, Bouchard J, Corlelli P, et al. The impact of subcutaneous sumatriptan on workplace productivity and non-workplace activity: results of a multinational study in patients with migraine. Glaxo Wellcome, 18 Dec 1996. (Data on file)
37. Gross MLP, Dowson AJ, Deavy L, et al. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs. Br J Med Econ 1996; 10: 231-46
38. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996 Mar; 36: 137-43
39. Langsdale T. Sumatriptan for migraine: assessing the outcomes. Inpharma 1996 Apr 20; 1033: 7-8
40. Payne K, Kozma CM, Lawrence BJ. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine: a retrospective cost-efficacy analysis. Pharmacoeconomics 1996 Jul; 10 (1): 59-71
41. Edmond M, Miller DW, Clements B, et al. Impact of sumatriptan on health-related quality of life and productivity in migraineurs [abstract]. Neurology 1995 Apr; 45 Suppl. 4: 465
42. Dahlof C, Bouchard J, Cortelli P, et al. Sumatriptan treatment in improving health-related quality of life in migraineurs. Glaxo Wellcome, 30 Dec 1996. (Data on file)
43. Jhingran P, Cady RK, Rubino J, et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996 Jan; 42: 36-42
44. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Man Care 1996; 2 (10): 1407-16
45. McGhan WF, Kitz DS. Cost-Benefit Analysis. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. Cincinnati (OH): Harvey Whitney Books Company, 1996: 60-75
46. Tfelt-Hansen P, Scheldewaert RG, Chazot G. Treatment of migraine attacks by oral lysine acetylsalicylate + metoclopramide (LAS + MTC) versus oral sumatriptan (S): socioeconomic consequences [abstract]. 6th Int Headache Res Sem 1995 Nov 17: 33
47. Miller DW, Martin BC, Loo CM. Sumatriptan and lost productivity time: a time series analysis of diary data. Clin Ther 1996; 18 (6): 1263-75
48. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs. Am J Man Care 1996; 2 (2): 139-43
49. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996; 36: 538-41
50. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996; 28: 171-7
51. Boureau F, Chazot G, Emile J, et al. Clinical efficacy of sumatriptan and its impact on quality of life comparison with the usual acute treatments of migraine [abstract]. In: Rose CF, editor. New advances in headache research 4. Proceedings of the 10th Migraine Trust Symposium: Sep 1994: London, England. London: Smith-Gordon and Company, 1994: 308
52. Bouchard J, Dahlof C, Heywood J, et al. A multinational investigation of subcutaneous sumatriptan: (IV) patient satisfaction. Glaxo Wellcome, 30 Dec 1996. (Data on file)
53. Gruffydd-Jones K, Hood C, Price D. Patient preference for subcutaneous and oral sumatriptan in the acute treatment of migraine [abstract]. Eur J Neurol 1995 Sep; 2 Suppl. 1: 65
54. Steiner TJ. Long-term cost-benefit assessment of anti-migraine drugs. Cephalalgia 1995 Oct; 15 Suppl. 15: 37-40
55. Larson LN. Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney Books, 1996: 44-59
56. Koopmanschap MA, Rutten FHE. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993; 4 (6): 446-54
57. Henry DA. Should indirect costs and benefits be included? [letter]. Pharmacoeconomics 1992; 1 (6): 462